Leaders in Global Health Honored at 9th Annual Project HOPE Gala
June 14, 2016 09:14 ET
|
Project HOPE
MILLWOOD, VA., June 14, 2016 (GLOBE NEWSWIRE) -- Project HOPE, the global health education and humanitarian assistance organization, today announced the recipients of the Project HOPE Global Health...
Ultra-fast, Meta-genomics Pathogen Detection Software for Diagnosing Infectious Diseases
May 26, 2016 14:22 ET
|
ARUP Laboratories
SALT LAKE CITY, May 26, 2016 (GLOBE NEWSWIRE) -- Scientists at the University of Utah, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer...
Battelle Infectious Diseases and Medical Countermeasure Work Awarded With New $59 Million Contract
May 23, 2016 14:25 ET
|
Battelle
COLUMBUS, OH--(Marketwired - May 23, 2016) - Battelle has again been chosen to protect our warfighters and the general public against dangerous infectious disease and chemical threats under a...
Johns Hopkins' Ebola Protective Suit Honored in Fast Company 'Innovation by Design Awards'
September 15, 2015 13:30 ET
|
Jhpiego
BALTIMORE, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Related video: https://youtu.be/kRab2bGahCE
The Johns Hopkins University's new personal protective suit for frontline health care workers in Ebola...
Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)
May 26, 2015 12:46 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
May 11, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
National Patient Safety Foundation DAISY Award Honorees Announced
April 21, 2015 09:37 ET
|
The National Patient Safety Foundation
BOSTON, April 21, 2015 (GLOBE NEWSWIRE) -- The National Patient Safety Foundation (NPSF) and the DAISY Foundation have announced the recipients of the National Patient Safety Foundation's DAISY Award...
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
March 24, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus
March 23, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...
Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
February 12, 2015 08:30 ET
|
AIM ImmunoTech Inc.
Ampligen® May Be an Important Candidate for EBOV Testing in West Africa
PHILADELPHIA, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or...